Adenylosuccinic acid tetraammonium (Synonyms: Adenylosuccinate tetraammonium; Aspartyl adenylate tetraammonium) |
Catalog No.GC64916 |
L'acide adénylosuccinique tétraammonium (adénylosuccinate; adénylate d'aspartyle) est un ribonucléoside monophosphate de purine et joue un rÔle dans le métabolite du cycle nucléotidique.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
Adenylosuccinic acid tetraammonium (Adenylosuccinate; Aspartyl adenylate) is a purine ribonucleoside monophosphate and plays a role in nucleotide cycle metabolite. Adenylosuccinic acid tetraammonium can be converted into fumaric acid through adenylosuccinate lyase. Adenylosuccinic acid tetraammonium has the potential for the study of duchenne muscular dystrophy(DMD)[1].
Adenylosuccinic acid tetraammonium (oral administration; 3-3000 µg/mL; 6 weeks) significantly improves the features of murine DMD, it decreases the number of centronucleated fibres, lipid accumulation, connective tissue infiltration and Ca2+ content of mdx tibialis anterior[1].
[1]. Timpani CA, et al. Adenylosuccinic acid tetraammonium therapy ameliorates murine Duchenne Muscular Dystrophy.Sci Rep. 2020 Jan 24;10(1):1125.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *